CytomX Therapeutics (NASDAQ: CTMX) saw its stock plummet 7.16% in Thursday's trading session following the release of its disappointing third-quarter 2025 financial results. The biotech company's earnings and revenue figures fell significantly short of analyst expectations, triggering a sell-off among investors.

The company reported a quarterly loss of $(0.09) per share, missing the analyst consensus estimate of $(0.05) by 95.65%. This represents a substantial decline from the $0.07 per share earnings reported in the same period last year. Revenue for the quarter came in at $5.963 million, falling well below the analyst estimate of $11.625 million and marking an 82.16% decrease compared to the $33.432 million reported in the previous year's quarter.

Despite the disappointing results, CytomX Therapeutics maintains a solid cash position, reporting $143.6 million in cash, cash equivalents, and investments at the end of the third quarter. The company expects this to provide a runway through the second quarter of 2027. Total operating expenses for Q3 2025 were $21.7 million, down from $29.3 million in the same period of 2024, reflecting cost-cutting measures. CytomX continues to focus on its clinical programs, with ongoing progress in the CX-2051 Phase 1 trial and a data update expected in the first quarter of 2026.